Latest progress

Salubris, today announced the first subject has been enrolled in the Phase 1 clinical trial of SAL0114, an independently-developed Class 1 new drug.

SAL0114 tablets are compound preparations for the treatment of severe depression and agitation in Alzheimer’s disease.

This phase 1 clinical study aims to evaluate the safety, tolerability and pharmacokinetics of SAL0114 in healthy subjects. If SAL0114 is approved to be marketed after a series of clinical trials, it will further meet potential clinical needs and provide patients with more drug options.